VRDN240920C20000
- 2.15
- +0.85+65.38%
Viridian Therapeutics Newsroom
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $44
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $45
Viridian Therapeutics Analyst Ratings
RBC Capital Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $44
RBC Capital Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
Buy Rating Affirmed for Viridian Therapeutics Following Positive THRIVE Study Results and Strong Market Potential for Veli
Goldman Sachs Maintains Buy on Viridian Therapeutics, Raises Price Target to $31
Goldman Sachs Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Raises Target Price to $31
B.Riley Financial Maintains Viridian Therapeutics(VRDN.US) With Hold Rating, Raises Target Price to $22
B. Riley Adjusts Viridian Therapeutics Price Target to $22 From $20, Maintains Neutral Rating
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $27 to $56
Oppenheimer Reaffirms Their Buy Rating on Viridian Therapeutics (VRDN)
Viridian Therapeutics Is Maintained at Buy by Needham
Buy Rating Affirmed for Viridian Therapeutics on Successful THRIVE Trial and Market Potential
Critical Insights From Viridian Therapeutics Analyst Ratings: What You Need To Know
Viridian Therapeutics Price Target Maintained With a $27.00/Share by HC Wainwright & Co.
Viridian Therapeutics Analyst Ratings
BTIG Research Adjusts Viridian Therapeutics Price Target to $56 From $46, Maintains Buy Rating
Buy Rating for Viridian Therapeutics Backed by Positive Clinical Results and Strong Market Prospects
Wedbush Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $42